Related references
Note: Only part of the references are listed.Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
Michael McClung et al.
AMERICAN JOURNAL OF MEDICINE (2013)
PTH-A Particularly Tricky Hormone: Why Measure It at All in Kidney Patients?
Giorgia Garrett et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Osteoporosis and adynamic bone in chronic kidney disease
Jorge B. Cannata-Andia et al.
JOURNAL OF NEPHROLOGY (2013)
BMD and Fracture Risk in CKD: Where Should We Go from Here?
Thomas L. Nickolas
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Benefits and Risks of Bisphosphonate Therapy for Osteoporosis
Sundeep Khosla et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Oral bisphosphonate use in the elderly is not associated with acute kidney injury
Andrew W. Y. Shih et al.
KIDNEY INTERNATIONAL (2012)
Arterial calcification and bone physiology: role of the bone-vascular axis
Bithika Thompson et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis
Steven Boonen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fracture risk assessment in patients with chronic kidney disease
S. A. Jamal et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Comparing the association of GFR estimated by the CKD-EPI and MDRD study equations and mortality: the third national health and nutrition examination survey (NHANES III)
Tariq Shafi et al.
BMC NEPHROLOGY (2012)
Bone and Kidney Disease: Diagnostic and Therapeutic Implications
Sophie A. Jamal et al.
CURRENT RHEUMATOLOGY REPORTS (2012)
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Risk Factors for and Complications of CKD and Mortality in the Kidney Early Evaluation Program (KEEP)
Lesley A. Stevens et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2011)
Using Proteinuria and Estimated Glomerular Filtration Rate to Classify Risk in Patients With Chronic Kidney Disease A Cohort Study
Marcello Tonelli et al.
ANNALS OF INTERNAL MEDICINE (2011)
Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease - The DIVINE study
Paul D. Miller et al.
BONE (2011)
Bisphosphonates: The first 40 years
R. Graham G. Russell
BONE (2011)
Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney Disease
Tamara Isakova et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure
Navdeep Tangri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Discriminants of Prevalent Fractures in Chronic Kidney Disease
Thomas L. Nickolas et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
Tamara Isakova et al.
KIDNEY INTERNATIONAL (2011)
Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study
P. N. Sambrook et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Cancer and renal insufficiency results of the BIRMA study
N. Janus et al.
BRITISH JOURNAL OF CANCER (2010)
FGF-23: More Than a Regulator of Renal Phosphate Handling?
Harald Jueppner et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Chronic Kidney Disease in Older People: Physiology, Pathology or Both?
Ahmed H. Abdelhafiz et al.
NEPHRON CLINICAL PRACTICE (2010)
Renal Insufficiency and Failure
Meletios A. Dimopoulos et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Fragility fractures in chronic kidney disease: An opinion-based approach
Paul D. Miller
CLEVELAND CLINIC JOURNAL OF MEDICINE (2009)
Adynamic bone disease: clinical and therapeutic implications
Joao M. Frazao et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2009)
High Prevalence of Stage 3 Chronic Kidney Disease in Older Adults Despite Normal Serum Creatinine
O. Kenrik Duru et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2009)
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
David M. Reid et al.
LANCET (2009)
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
Steven Boonen et al.
KIDNEY INTERNATIONAL (2008)
Bisphosphonate nephrotoxicity
Mark A. Perazella et al.
KIDNEY INTERNATIONAL (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Preclinical evidence for nitro gen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney:: Implications for renal safety
Anke Luehe et al.
TOXICOLOGY IN VITRO (2008)
Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases
Timo K. Joensuu
UROLOGIA INTERNATIONALIS (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient
Michael Bodmer et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Renal osteodystrophy, phosphate homeostasis, and vascular calcification
Keith A. Hruska et al.
SEMINARS IN DIALYSIS (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial
Sophie A. Jamal et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Renal function and risk of hip and vertebral fractures in older women
Kristine E. Ensrud et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Association of kidney function with incident hip fracture in older adults
Linda F. Fried et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women
Burcu Yanik et al.
RENAL FAILURE (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Medical progress - Assessing kidney function - Measured and estimated glomerular filtration rate
Lesley A. Stevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Drug-associated renal dysfunction and injury
D Choudhury et al.
NATURE CLINICAL PRACTICE NEPHROLOGY (2006)
Intravenous ibandronate injections in postmenopausal women with osteoporosis - One-year results from the dosing intravenous administration study
Pierre D. Delmas et al.
ARTHRITIS AND RHEUMATISM (2006)
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials
PD Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma
D Henley et al.
INTERNAL MEDICINE JOURNAL (2005)
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
PD Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Preclinical perspectives on bisphosphonate renal safety
JJ Body et al.
ONCOLOGIST (2005)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Arterial calcifications and bone histomorphometry in end-stage renal disease
GM London et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy
KA Hruska et al.
SEMINARS IN NEPHROLOGY (2004)
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
LS Rosen et al.
CANCER (2003)
Toxic acute tubular necrosis following treatment with zoledronate (Zometa)
GS Markowitz et al.
KIDNEY INTERNATIONAL (2003)
Relationship between age, renal function and bone mineral density in the US population
S Klawansky et al.
OSTEOPOROSIS INTERNATIONAL (2003)
Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment
EJ Kingdon et al.
RHEUMATOLOGY (2003)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Highly potent geminal bisphosphonates.: From pamidronate disodium (Aredia) to zoledronic acid (Zometa)
L Widler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Anticancer drug-induced kidney disorders - Incidence, prevention and management
PE Kintzel
DRUG SAFETY (2001)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
